Biohaven Ltd. (NYSE: BHVN) is a Healthcare company (Biotechnology) with a market capitalization of $2.0B. The Maz Rating grades it against the other companies in its sector.
Biohaven Ltd.'s current Maz Rating and its five factor grades are for members: log in to see them.
Biohaven Ltd. has been loss-making over the last twelve months, so it has no meaningful P/E. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -2271.9%, return on invested capital of -255.0% and a free cash flow yield of -23.7%. On the balance sheet: a debt-to-equity ratio of -3.06 and a current ratio of 3.05. Over the past 52 weeks the share price ranged from $8.03 to $18.24, with a beta of 3.13.
Biohaven Ltd. does not currently pay a dividend.
25 Wall Street analyst ratings cover the stock: 16 Buy, 8 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.